PDCD1 and neoplasm: We demonstrated that pre-treatment TILs predicted patient survival and post-treatment TILs correlated with clinical outcome and highlighted the important role of B cells and CD8+ T cells in mediating anti-tumor immune responses during PD-1 blockades therapy, supporting the potential for novel therapies directed at B cells and CD8+ T cells29,32.